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Abstract 
Parkinson’s disease is a progressive brain disorder due to the degeneration of dopaminergic neurons in the 
substantia nigra. Parkinson's disease is a progressive brain disorder due to the degeneration of 
dopaminergic neutrons in the SN.  The accumulation of aggregated forms of α-synuclein protein into 
Lewy bodies is one of the characteristic features of this disease although the pathological role of any such 
protein deposits in causing neurodegeneration remains elusive.  Here, the effects of different 
apolipoprotein E isoforms (apoE2, apoE3, apoE4) on the aggregation of α-synuclein in vitro were 
examined using thioflavin T assays and also an immunoassay to detect the formation of multimeric forms. 
Our results revealed that the aggregation of α-synuclein is influenced by apoE concentration. At low 
concentrations of apoE (<15 nM), all of the isoforms were able to increase the aggregation of α-synuclein 
(50 µM), with apoE4 showing the greatest stimulatory effect. This is in contrast to a higher concentration 
(>15 nM) of these isoforms, where a decrease in the aggregation of α-synuclein was noted. The data show 
that exceptionally low levels of apoE may seed α-syn aggregation, which could potentially lead to the 
pathogenesis of α-synuclein-induced neurodegeneration. On the other hand, higher levels of apoE could 
potentially lower the degree of α-synuclein aggregation and confer protection. The differential effects 
noted with apoE4 could explain why this particular isoform results in an earlier age of onset for 
Parkinson’s disease.  
 
Keywords: Parkinson’s disease; Lewy body; α-synuclein; apolipoprotein E; aggregation 
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Introduction 
Parkinson’s disease (PD), a progressive neurodegenerative disorder that impairs movement, and affects 
over 6 million people globally. Neuropathological features of  idiopathic PD, the most common form of 
Parkinson’s, include the  presence of Lewy bodies (LBs) and the loss of dopaminergic neurons from the 
substantia nigra (SN) in the surviving neurons [1]. LBs are intracellular inclusion bodies that contain 
fibrils composed of a protein called α-synuclein (α-syn) [1-3]. Pathological changes involving α-syn are 
also found in more widespread areas of the brain in dementia with Lewy bodies (DLB) and in glial cells 
in multiple system atrophy (MSA) [3]. Duplication,
 
triplication and mutation of the SNCA, the gene 
encoding α-syn,  are all causes of hereditary forms of either PD or DLB [4]. The over expression of α-syn 
in transgenic animals produces a phenotype resembling PD, with SN degeneration, movement problems, 
and responsiveness to therapy with the drug L-dopa, which is still the mainstay of treatment for patients 
with PD [5,6]. The secondary structure and aggregation state of α-syn vary in response to its environment. 
In aqueous solution, α-syn has been reported to exist as a ‘natively unfolded’ protein, while contact with 
acidic phospholipids induces transformation into a structure containing α-helices [7]. Most notably, the 
protein present in LBs is found in the form of insoluble fibrils that contain a high content of β-pleated 
sheet structure [1-3]. Moreover, prefibrillar forms of α-syn often referred to as ‘soluble oligomers’ are 
toxic to nerve cells [8, 9]. These observations suggest that α-syn plays a pivotal role in the development 
of PD and the other ‘α-synucleinopathies’. 
 
Apolipoprotein E (apoE), the most abundant apolipoprotein in the human brain, acts to maintain 
cholesterol homeostasis. It is 299 amino acids in length, and exists in three different isoforms, based on 
the amino acid residues present at positions 112 and 158. These are apoE2 with Cys at both positions, 
apoE3 with Cys-112 and Arg-158, and apoE4 with Arg at both positions [10]. The presence of one or 
more apoEε4 alleles increases the risk of developing late-onset Alzheimer’s disease, reduces age of onset, 
and increases cerebral β-amyloid (Aβ) plaque load [11]. ApoE has also been reported to enhance amyloid 
fibril formation in vitro by binding to Aβ, and to increase the phosphorylation of tau and promote 
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neurofibrillary tangle formation, with apoE4 consistently showing the greatest effect [12-14]. ApoEε4 is 
also a risk factor for other neurological disorders, such as multiple sclerosis [15-17]. A possible role for 
apoE in PD is less well documented, but apoE is present in neurons and LBs of the SN in both PD and 
incidental Lewy body disease (iLBD) (a possible precursor to PD) along with its receptor, low-density 
lipoprotein receptor-related protein 1 (LRP1), which is over expressed in these conditions [18]. ApoE is 
considered to have a neuroprotective role by preventing apoptosis in neurons and the anti-apoptotic 
mechanism is initiated when apoE binds to LRP1 [19]. Thus alterations in lipoprotein homeostasis could 
be an early event during the pathogenesis of PD and apoE could have a positive impact on the survival of 
SN neurons. On the other hand, it has been reported that deletion of apoE decreases α-syn aggregation in 
the brains of transgenic mice and boosts overall survival [20] suggesting that high levels of ApoE 
concurrent with high levels of aggregated α-syn may be a risk factor for PD. It has also been noted that 
PD patients who carry at least one apoEε4 allele are more vulnerable to the development of dementia than 
non-carriers [21, 22]. PD patients with apoEε4 also have an earlier age of disease onset [23, 24]. 
 
Although the reports mentioned above have suggested possible links between apoE, α-syn and PD, there 
are no previous publications examining the direct effects of apoE on aggregation of α-syn in vitro. Here, 
we have monitored the aggregation of α-syn over time in the presence of different amounts of each of the 
isoforms of apoE. The results clearly show that low concentrations of apoE stimulate α-syn aggregation, 
whereas higher concentrations cause inhibition. Amongst the different apoE isoforms, low concentrations 
of apoE4 were found to have the greatest effect on stimulation of α-syn aggregation. 
 
Materials and Methods 
The different isoforms of ApoE were supplied by Sigma (apoE2; SRP4760, apoE3; SRP4696 and, apoE4; 
A3234). Biotinylated C211 was prepared using a Sigma biotinylation kit (KB101), following the 
instructions of the manufacturer. Other materials included anti-α-synuclein (C211) mouse monoclonal 
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antibody (Santa Cruz, sc-12767),  anti-α-synuclein  Syn 1 mouse monoclonal antibody (BD Tranduction 
Labs, 610787) and MonoQ 5/50 GL and Superdex 200 10/300 columns (GE healthcare). 
 
Production of recombinant α-synuclein protein 
Recombinant α-syn (R-α-syn) protein was produced by using a pET11a expression vector introduced into 
E.Coli. An agar plate containing chloramphenicol and carbenicillin (CM+CB) was streaked with pET11a 
α-syn glycerol and incubated overnight at 37 °C. A colony was transferred to a tube containing 5 ml 
Luria-Bertani broth (CM+CB) and incubated overnight. 1 ml of overnight culture was transferred into 100 
ml LB broth (CM+CB) and incubated overnight at 37 °C. 800 ml of LB broth (CM+CB) were placed into 
a large shaking incubator, at 200rpm and left to reach  37 °C for about 20 min. Then, 50 ml of overnight 
culture were added into each flask and the OD600  measured approximately every 30 min until it reached 
~0.5. This was followed by induction with IPTG for 2 h at 37 °C. After 2 h of incubation, the cultures 
were centrifuged at 3000 x g for 30 min at 4 °C. The supernatant was discarded and each pellet was 
resuspended in 10 ml of cell suspension buffer, pooled together, and stored frozen at -80 °C. Resuspended 
pellets were thawed in a 37 °C water bath, but were not allowed to reach 37 °C. The warmed tube was 
placed on ice and its contents were sonicated for 6×20 sec bursts, with 20 sec intervals. After the second 
sonication, 10 µl of PMSF was added per 1 ml of culture. The samples were transferred into 8 ml glass 
ultracentrifuge tubes and centrifuged at ~50,000 g for 2 hrs at 4 °C to separate the lysate containing R-α-
syn from E.Coli proteins. 500 µl of E. Coli lysate expressing α-syn was applied to the MonoQ 5/50 GL 
column and bound proteins were eluted with a linear gradient of KCl (0 to 0.5 M) at a flow rate of 0.5 
ml/min. Protein concentration in each fraction was measured by absorbance at 280 nm. Fractions 
containing α-syn , detected by SDS-PAGE gel,  were pooled and further purified on a gel filtration 
column (Superdex 200 10/300).  The purity of the final product was estimated as >90 % by SDS-PAGE 
and immunoblotting. 
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Thioflavin T assay 
A ThT stock solution (2.5 mM) was prepared by adding 8 mg ThT to 10 mL phosphate buffer (10 mM 
phosphate, 150 mM NaCl, pH 7.0), filtered through a 0.2 μm syringe filter, and stored at 5 °C in a foil-
wrapped tube for not longer than one week. For each experiment, the ThT stock solution was diluted with 
phosphate buffer to generate the working solution (0.05 mM). In the ‘continuous’ ThT assay, 15 µl of 
ThT working solution was mixed with R-α-syn solution and the fluorescence intensity of ThT was 
monitored by excitation at 440 nm and emission at 482 nm over a 5 day incubation period at intervals of 
10 mins. In the ‘stopped’ ThT assay, the R-α-syn solution was incubated at 37 °C and samples were 
removed after set incubation time periods prior to the addition of 50 µl of ThT to each sample. The 
intensity of ThT fluorescence was then measured as before. The mean % aggregation was calculated 
relative to R-α-syn alone 
 
Immunoassay for measuring oligomeric/polymeric α-synuclein 
An ELISA plate was coated by overnight incubation with 1 µg/ml of non-biotinylated anti-α-syn C211 
antibody, diluted in 200 mM NaHCO3, pH 9.6, containing 0.02% (w/v) sodium azide, at 4 °C overnight. 
The wells were then washed 4 times with PBS-T and incubated for 2 h at 37 °C with 200 µl/well of 
freshly prepared blocking buffer. The plate was washed again with PBS-T, and 100 µl of the sample in 
each well incubated at 37 °C for 2 h. After washes with PBS-T, 100 µl/well of biotinylated C211 diluted 
to 1 µg/ml in blocking buffer was added and  incubated at 37 °C for 2 h. The plate was washed 4 times 
with PBS-T and incubated with 100 µ/well of streptavidin-europium for 1 h at RT on a shaker. The plate 
was washed 4 times with PBS-T and 100 µl of europium enhancer (PerkinElmer Life Sciences Inc. USA) 
added to each well and the plate incubated for 10 min on a shaker. The time-resolved fluorescence (TRF) 
assay was performed by using the standard conditions for detection of europium fluorescence (excitation 
at 340 nm, and fluorescence emission at 615 nm) in a Perkin Elmer Wallac Victor2
TM 
plate reader.     
Data analysis 
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Data are expressed as mean ±SEM, analysed by one-way ANOVA to evaluate the differences between 
group means. Then, Tukey’s HSD  method, as a single-step multiple comparison procedure,  was used in 
conjunction with ANOVA (XLSTAT product) to find  the mean levels of α-syn aggregation that are 
significantly different from each other at the four concentrations of each of the different apoE isoforms 
(p-value < 0.01) 
 
Results 
Anion exchange chromatography was effective in the initial purification of the cell lysate to yield R-α-
synuclein as the main product (figure 1a) seen on a coomassie blue stained SDS-PAGE Gel.  A further 
purification step using size exclusion chromatography improved the purity of the final R-α-syn to 
homogeneity as indicated by a single band (figure 1b) on a silver stained SDS-PAGE Gel.  
Immunoblotting (figure 1c) using two different α-synuclein specific monoclonal antibodies confirmed the 
identity. 
 
Two different thioflavin T (ThT) assays were employed to monitor the aggregation of α-syn in the 
presence of each of the different apoE isoforms. For the ‘continuous’ assay, R-α-syn, apoE and ThT were 
simultaneously present throughout the assay, while in the ‘stopped’ assay R-α-syn was preincubated with 
apoE prior to addition of ThT for recording fluorescence intensity. This ‘stopped’ assay method was used 
to determine whether the presence of ThT has any influence on α-syn aggregation. Statistical analysis was 
performed using Tukey’s HSD method. 
 
In the continuous ThT assay, the lower concentrations of apoE tested (1, 5 and 15 nM) consistently 
increased the aggregation of α-syn (which was present at 50 μM) whereas the highest concentration of 
apoE (50 nM) inhibited α-syn aggregation (Figure 2). In all cases, the aggregation typically proceeded 
(Figure 2a) with a time delay of at least 24 h, reflecting the need for a nucleation process. This was 
followed by biphasic behaviour, exhibiting a slow aggregation phase in the next 36 h eventually leading 
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to a rapid aggregation process at 60-80 h. The length of the nucleation phase was not greatly affected by 
the presence of apoE, suggesting that apoE does not have any major influence on the onset of α-syn 
aggregation. The main effect of apoE was to enhance or inhibit the level of the ThT fluorescence signal 
seen towards the end of the incubation period, which reflects the final number of fibrils formed. The 
aggregation process approached completion by 120 h, which was taken as the end point. Figure 2b 
presents the percentage of α-syn aggregation (relative to R-α-syn alone) at the end of this 120 h 
incubation, in the presence of the different apoE isoforms. A small differential effect was seen for the 
different isoforms, with the lowest concentration of apoE4 (1 nM) having the greatest stimulatory effect 
on α-syn fibril formation. 
 
In the stopped ThT assay, the ThT signal seen at the end of the time course (120 h), reflecting the amount 
of α-syn fibrils formed, was increased in the presence of low concentrations of apoE (15 nM or less) and 
decreased at the highest apoE concentration (50 nM) (Figure 3). The kinetics of the aggregation in the 
absence of ThT exhibited a similar biphasic profile to that observed in the presence of ThT for all of the 
isoforms, as illustrated by apoE2 (Figure 3a). Analysis of the final percentage (at 120 h incubation) of 
α-syn aggregation (figure 3b) in the presence of the different apoE isoforms, relative to R-α-syn alone, 
confirms that apoE4 has the greatest stimulatory effect on α-syn aggregation at 1 nM apoE concentration. 
As can be seen in Figures 2 and 3, apoE4 at 1 nM concentration significantly increases the aggregation of 
α-syn relative to the other isoforms in both types of ThT assay. 
 
In an attempt to verify these results, an alternative method was employed to monitor α-syn aggregation. 
The same samples from the stopped ThT assay were also analyzed by an immunoassay technique for 
determination of multimeric α-syn. This involves capture of α-syn aggregates with C211 anti-α-syn 
antibody followed by detection with a biotinylated form of the same antibody. Monomeric α-syn does not 
give a signal in this assay [25]. The data from this experiment are presented in Figure 4, which also 
includes an overall summary (figure 4d) of the effect of each apoE isoform. The results from this assay 
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were very similar to those obtained with both of the ThT assays. The kinetic profiles (Figure 4a-c) were 
also comparable to those observed with both of the ThT assays (Figure 2 and 3). The ThT assay 
specifically detects β-pleated structures, whereas the sandwich immunoassay is not expected to 
distinguish between different secondary structures present in the aggregate but selects for any of the 
multimeric forms. At low apoE concentrations, the rank order (figure 4d) for stimulation of α-syn 
aggregation was always apoE4>apoE3>apoE2. 
 
All of the data from these three assays are consistent with each other and confirm that apoE4 has the 
greatest stimulatory effect on α-syn aggregation, at low apoE concentrations. Tukey’s HSD test confirms 
(Figures 2b, 3b, and 4d) that the stimulatory effect of apoE4 is always significantly greater than that of the 
other isoforms at 1 nM (indicated by the different letters ‘a’ and ‘b’), but the effects of the apoE isoforms 
are not always significantly different from each other at the higher concentrations (marked by bars with 
the same letter ‘a’). The average of the percentage α-syn aggregation over all three assays, as determined 
at the end of the incubation time course, has been plotted for each apoE concentration (Figure 5). Here, 
the data for apoE2, apoE3 and apoE4 have also been combined, so that the overall effects of different 
concentrations of apoE on α-syn aggregation can be appreciated. The results clearly show that low 
concentrations of apoE stimulate α-syn aggregation, whereas the highest concentration causes some 
inhibition. 
 
Discussion 
In this study, we examined the effects of each isoform of apoE on the aggregation of recombinant α-syn 
(R-α-syn) in vitro. For this purpose, we established two different ThT assays (for detection of β-pleated 
sheet fibrils) and an immunoassay (for detection of multimeric α-syn). The data from all these assays 
were in remarkably close agreement, and show that low concentrations of apoE increase the amount of 
late-stage aggregates formed, with apoE4 having the greatest effect, in contrast to higher concentrations 
of apoE, which inhibit α-syn aggregation. 
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One possible explanation for these effects of apoE is that it can also self-aggregate, with apoE4 doing so 
at a faster rate than the other isoforms, and apoE2 aggregating the slowest [26]. If the aggregated form of 
apoE acts as a ‘nucleus’ for α-syn aggregation, this could explain why apoE4 appears to enhance 
aggregation to a greater degree than the other isoforms. Under appropriate conditions, apoE could self-
aggregate, or co-aggregate with α-syn, and so act as a ‘seed’ for other α-syn molecules to become 
incorporated into the resulting β-sheet aggregates. However, this idea conflicts with the fact that apoE 
self-aggregation is more closely related to α-helical interactions than the formation of β-sheet structures 
[26] and so might not be expected to ‘seed’ β-sheet formation. Also, this type of mechanism cannot easily 
explain why the highest concentration of apoE actually inhibited α-syn aggregation.  
 
It is also possible that α-syn interacts directly with apoE, with the three isoforms of the latter having 
differential binding properties, and this could also explain the effects seen on α-syn aggregation. It is 
interesting to note that apoE has been reported to bind directly to intermediate aggregates or ‘oligomers’ 
of the β-amyloid peptide (Aβ) associated with Alzheimer’s disease, with apoE4 having the greatest 
affinity for such binding [27]. Given the fact that Aβ and α-syn both have the ability to form highly 
similar β-pleated sheet structures, which can even be recognised by the same monoclonal antibody [9], it 
would not be surprising if apoE also had the ability to bind to oligomeric α-syn. The kinetic profiles 
follow a similar pattern for all three assays, and so it can be argued that the aggregation predominately 
results in the formation of β-pleated sheet structures.  Furthermore, as the onset of aggregation was 
detected at similar time points for all three assays, it could be inferred that in the nucleation phase any 
small seed structures present must be loosely associated monomeric forms of α-syn and free of the more 
strongly associated β-pleated sheet.   
 
Among the different apoE isoforms, low concentrations of apoE4 were found to stimulate α-syn 
aggregation to a greater extent than the other isoforms. This effect of apoE4 on α-syn aggregation could 
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help to explain why apoEε4 is a risk factor for earlier onset of PD [24], which certainly warrants further 
investigation.  
 
Taken together, the results from this study have revealed that a possible direct molecular interaction 
between soluble α-syn and various apoE isoforms can influence the extent of α-syn aggregation in vitro. 
A close agreement between the ThT assays and the results from the immunoassay underpins the fact that 
the α-syn species being detected were oligomeric in nature. Such oligomeric forms are well reported to be 
neurotoxic [28].  Post-mortem ventricular CSF of  individuals [32], without evidence of dementia or 
parkinsonism,  has an apoE content of around 6.9 µg/ml compared to a lower value of 5.7 µg/ml for PD 
group.  The highest concentration (50 nM) we tested is between 3 to 4 to fold below such levels but 
caused suppression of α-synuclein aggregation.  However in the lower nM range (<50 nM) the 
aggregation was stimulated indicating unusually low levels of ApoE may potentially contribute in early 
seeding  of the deposition of  oligomeric forms of the  α-synuclein.  Lower apoE levels in the CSF of a 
PD animal model relative to normal animals have been documented [33]. In a transgenic mouse model of 
α-synuclein the deletion of apoE expression also decreased the levels of insoluble, in favour of soluble, α-
synuclein and  slowed the  neurodegeneration [20]. The absolute intraneuronal levels of apoE in PD group 
are probably a more important consideration but unknown. The mechanism of how apoE, at very low 
levels, could contact the cytoplasmic α-synuclein is obscure. At present, evidence is lacking in the 
literature to support the view that the α-syn and apoE can interact directly in vivo. One of the main 
reasons for this is the fact that α-syn has been thought historically to be a cytoplasmic protein, whereas 
apoE is extracellular. However, it is now clear that extracellular forms of α-syn do exist [29], and could 
be involved in a ‘prion-like’ seeding mechanism for the spread of α-syn pathology to adjacent parts of the 
brain [30]. Thus extracellular interactions between α-syn and apoE could influence the aggregation of the 
former, and have an effect on PD pathogenesis. Also, it is feasible that an internalisation mechanism for 
apoE may bring the two molecules together. In this context, it is interesting to note that altered neuronal 
apoE trafficking has been implicated to occur in PD and is speculated to be involved in α-syn deposition 
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[18]. Many fundamental questions remain unanswered at this stage due to uncertainties in  mechanism of 
action for the toxicity of oligomeric α-synuclein and technological challenges in studying α-syn 
aggregation at intracellular level [31].  In our findings, while low levels of apoE aggravated the extent of 
α-syn aggregation, the higher level tended to supress aggregation. Neurodegeneration induced by 
overexpressed α-syn in transgenic mice also caused higher levels of apoE [20]. Could this be the body’s 
natural defence to reduce aggregation and hence help combat PD?   
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Figure legends 
Figure 1. 
(A) Coomassie brilliant blue stained SDS-PAGE gel of the anion exchange purified cell lysate. (B) 
Silver stained SDS-PAGE gel of the purified final R-α-Synuclein.  Western blots of the final product 
using anti-α-syn syn1 (C) and anti-α-syn C211 (D) monoclonal antibodies. 
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Figure 2. 
A. α-syn (50 µM) aggregation curves recorded  in the presence of ThT at different concentrations of 
apoE2.  The curves at time point 120 hrs reading from top to bottom represents apoE 
concentrations of 1, 5, 15, 0, and 50 nM. The very bottom curve represents background signal 
without any apoE and α-synuclein. 
B. Percentage of end-stage α-syn aggregation seen in the presence of different apoE isoform 
concentrations.  The α-syn (50 µM) was incubated for 120 h in the presence of both ThT and each 
given concentration of apoE. Data show mean +/- SEM (n = 3) percentage aggregation, relative to 
α-syn alone. Within each defined concentration of apoE, means with different letters are 
significantly different (Tukey’s HSD, p<0.01). 
 
Figure 3. 
A. α-syn (50 µM) aggregation curves at indicated concentrations of apoE2. ThT was added after 
incubation of the α-syn with apoE. The curves at time point 120 hrs reading from top to bottom 
represents apoE concentrations of 1, 5, 15, 0, and 50 nM. 
B. Percentage of end-stage α-syn aggregation seen in the presence of different apoE isoform 
concentrations prior to adding ThT.  The α-syn (50 µM) was incubated, with given concentration 
of apoE, for 120 h in the absence of ThT.  Data show mean +/- SEM (n = 3) percentage 
aggregation, relative to α-syn alone. Within each defined concentration of apoE, means with 
different letters are significantly different (Tukey’s HSD, p<0.01). 
Figure 4.  
(A-C)  Effect of apoE isoforms at different concentrations of (A) apoE2, (B) apoE3 and (C) 
apoE4 on the kinetics of 50µM α-synuclein aggregation using sandwich capture 
immunoassay.  Europium was used for TRF measurements. The curves at time point 180 
hrs from top to bottom represents apoE concentrations of 1, 5, 15, 0, and 50 nM. 
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 (D) Percentage of end-stage α-syn aggregation seen in the presence of different apoE isoform 
concentrations in the immunoassay for multimeric ThT. The α-syn (50 µM) was 
incubated for 120 h in the presence of each given concentration of apoE. Data show mean 
+/- SEM (n = 3) percentage aggregation, relative to α-syn alone. Within each defined 
concentration of apoE, means with different letters are significantly different (Tukey’s 
HSD, p<0.01). 
Figure 5.  
Percentage of end-stage α-syn aggregation seen in the presence of different concentrations of apoE. The 
data presented in Figures 1b, 2b and 3d have been averaged over all three apoE isoforms, and over all 
three assays. Data are plotted as mean +/- SEM. Across the different concentrations of apoE, means with 
different letters are significantly different (Tukey’s HSD, p<0.01). 
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